首页 > 资讯 > GPhA指出仿制药为美国公众节省更多费用

出自识林

2014-09-11 Lachman CONSULTANTS

国会预算局（CBO）上月的报告显示在医疗卫生方面的花费骤降。所节省的费用中很大一部分得益于仿制药的使用。今年仿制药协会的年度费用节省报告显示，消费者（包括联邦政府）在2013年共节省了2390亿美元，比2012年的节省量增加了14%。

2004-2013年仿制药节省的费用
来源：IMS医疗卫生情报协会的报告

在过去10年间，因使用仿制药所节省的费用已到达15000亿美元。

“这份报告证实了仿制药所节省的费用在保持增长。在每年节省的总费用不断增长的同时，这份报告还显示仅2013年上市的新仿制药就为美国健康系统节省了1400亿美元。已上市的仿制药产品也在持续节省费用，在2013年它们节省了980亿美元。”（GPhA发布）

这份报告在Hatch-Waxman法案（药品价格竞争与专利期补偿法，1984）颁布30周年纪念之际发表。这是个好消息，并且说明该法案在节省国家医疗健康费用方面的重要性。这是成功的（如果不是最成功的）价格立法之一，自颁布之日起就不断减缓医疗健康费用增加的趋势。

仿制药企业和GPhA一直以来持续支持仿制药办公室的工作，在他们的努力之下，为市场带来更多价格实惠的仿制药。

Lachman CONSULTANTS - Bob Pollock先生 2014-09-10
校译：识林-椒 2014-09-11

GPhA Annual Cost Savings Report Shows Larger Savings for the US Public
Written by Bob Pollock • September 10, 2014

The Congressional Budget Office (CBO) report last month indicated that the cost of health care programs has slowed sharply. A large part of the savings is attributed to the cost savings realized through the use of generic drugs. This year's GPhA Cost Savings report showed that consumers (including the US Government) saved $239 million alone in 2013 an increase of 14% over the savings seen in 2012.

Generic Cost savings 2004-2013

Source: IMS Institute for Healthcare Informatics' report

The 10 year savings from generic availability is reported at $1.5 trillion over the last 10 year period.

“The report confirms that the story of generic savings remains one of growth. In addition to the yearly growth of the savings totals, the report reveals that new generic products coming to market in 2013 saved the U.S. health system $140 billion alone. Established generic products continue to provide cost savings and, in 2013, they accounted for $98 billion in savings.”(the GPhA release says)

This report comes days before the 30th anniversary of the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984). The news is good and points out the importance of the legislation in terms of reducing associated health care costs in this country. This is one of (if not the most) successful piece of legislation with regards to reducing the trend of increases in health care costs that has ever been enacted.

The generic drug industry and GPhA continue to support the Office of Generic Drugs program in its efforts to bring more affordable generic drug products to market.